14.08.2018
Biotest AG DE0005227235
DGAP-News: Biotest AG: Biotest increases revenues to EUR 200.7 million in the first half of 2018
DGAP-News: Biotest AG / Key word(s): Half Year Results
Biotest AG: Biotest increases revenues to EUR 200.7 million in the first
half of 2018
14.08.2018 / 09:00
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
PRESS RELEASE
Biotest increases revenues to EUR 200.7 million in the first half of 2018
- EBIT of EUR 0.6 million despite expenses of EUR 23.7 million for the
Biotest Next Level project
- Successful qualification of the process plant for the purification of IgG
Next Generation
Dreieich, 14 August 2018. In the first half of 2018, the Biotest Group
reported revenue of EUR 200.7 million. This is an increase of 18.0 % over
the EUR 170.1 million in sales during the same period of the previous year.
The product recall of human albumin had a negative effect on the development
of sales in the first half of the previous year.
EBIT in continuing operations was EUR 0.6 million in the first half year of
2018 (same period of the previous year: EUR -32.1 million). The EBIT of the
first half year includes expenses for the Biotest Next Level project of EUR
23.7 million (same period of the previous year: EUR 25.8 million). The EBIT
in the previous year was also negatively impact by the albumin recall. In
the core segment Therapy EBIT was positive at EUR 1.3 million in the first
six months of the 2018 financial year (same period of the previous year: -
EUR 25.5 million).
Earnings after taxes of discontinued operations was EUR -8.0 million (same
period of the previous year: EUR -30.2 million).
On August 1, the sale of the US companies was completed. Since this was
foreseeable towards the end of June 2018, a profit of approximately
EUR 158 million was recorded in the first half of the year. Earnings after
taxes of discontinued operations therefore amounted to EUR 193.7 million in
the first half of 2018 after EUR 12.3 million in the comparable period of
the previous year.
In the first half year of 2018, Biotest Group's total earnings after taxes
(EAT) was EUR 185.7 million (same period of the previous year: EUR -17.8
million). This results in earnings per share of EUR 4.68 after EUR -0.46 in
the first half of the previous year.
As announced, during the first half of 2018 Biotest further expanded its
network of the Group's own plasma collection centres in Europe. In the first
half of 2018, Biotest opened two plasmacollection centres in Czechia. Now
there are 19 collection centres in total in Europe to ensure the long-term
supply of plasma.
The major expansion project Biotest Next Level was further advanced in the
first half year of 2018. The first process system for purification of the
polyspecific immunoglobulin IgG Next Generation was successfully qualified
in June 2018 and transferred to Biotest.
Outlook:
For the 2018 financial year, the Board of Management expects sales of
continuing operations to increase by a mid-single-digit percentage. Earnings
will be influenced by various factors in 2018. Besides the deliberately
further increased expenses as part of the Biotest Next Level (BNL) expansion
project of EUR 60 to 70 million - including the associated research and
development costs - the continued tense situation in the crisis regions,
especially in the Middle East, could be noticeable.
Due to the above influences, the Board of Management anticipates EBIT of
continuing operations in the range of EUR 10 to 12 million. Without the
extraordinary impact from the BNL project, the adjusted EBIT would be
approximately EUR 70 to 80 million. For 2018, the Board of Management
expects a return on capital employed (ROCE) of approx. 1.2 % and cash flow
from operating activities of approximately EUR 10 million.
About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value
added chain that extends from pre-clinical and clinical development to
worldwide sales, Biotest has specialised primarily in the areas of clinical
immunology, haematology and intensive medicine. Biotest develops and markets
immunoglobulins, coagulation factors and albumins based on human blood
plasma. These are used for diseases of the immune and haematopoietic
systems. In addition Biotest develops monoclonal antibodies in the
indications of cancer of plasma cells and systemic lupus erythematosus which
are produced by recombinant technologies. Biotest has more than 1,600
employees worldwide. The preference shares of Biotest AG are listed in the
SDAX on the Frankfurt stock exchange.
IR contact
Dr. Monika Buttkereit
phone: +49-6103-801-4406
email: [email protected]
PR contact
Dirk Neumüller
phone: +49-6103-801-269
email: [email protected]
Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com
Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Frankfurt (Prime Standard)
Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart,
Tradegate
Disclaimer
This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments. The
forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and assumes
no obligation to do so.
---------------------------------------------------------------------------
14.08.2018 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Germany
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
E-mail: [email protected]
Internet: http://www.biotest.de
ISIN: DE0005227235, DE0005227201
WKN: 522723, 522720
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
713927 14.08.2018
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Biotest AG ISIN: DE0005227235 können Sie bei EQS abrufen
Gesundheit , 522723 , BIO3 , XETR:BIO3